Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A tetrahydroquinoline derivative according to Formula 1,

Formula I

or a pharmaceutically acceptable salt thereof, wherein

R¹ and R² are H or Me

R³ is H, hydroxy, (1-4C)alkoxy,

R⁴ is H, OH, or (1-4C)alkoxy,

R⁵ is OH, (1-4C)alkoxy or R⁷,

with the proviso that if R⁴ is H, R⁵ is not OH or (1-4C)alkoxy

R⁶ is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, or (1-6C)alkyl,

wherein the (2-5C)heteroaryl and the (6C)aryl are optionally substituted with one or more substituents selected from hydroxyl, amino, halogen, phenyl, (1-4C)alkyl, (1-4C)alkoxy, or (1-4C)(di)alkylamino,

R⁷ is amino, (di)(1-4C)alkylamino, (2-5C)heteroarylcarbonylamino, (2-

5C)heteroarylcarbonyloxy, R⁸-(2-4C)alkoxy, R⁹-methylamino or R⁹-methoxy

R⁸ is amino, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl, (2-

6C)heterocycloalkylcarbonylamino, or (1-4C)alkoxycarbonylamino and

Application No. 10/540,336 Amendment dated May 5, 2009

Reply to Office Action of November 5, 2008

R⁹ is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (2-5C)heteroaryl, optionally substituted with one or more (1-4C)alkyl substituents, or (6C)aryl.

Docket No.: 2002.750US

- 2. (Cancelled).
- 3. (Cancelled).
- 4. (Previously Presented) The tetrahydroquinoline derivative of claim 1 wherein R⁸ is amino, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl or (2-6C)heterocycloalkylcarbonylamino.
- 5. (Previously Presented) The tetrahydroquinoline derivative of claim 1 wherein R⁷ is (di)(1-4C)alkylamino, R⁸-(2-4C)alkoxy, R⁹-methylamino or R⁹-methoxy.
- 6. (Previously presented) The tetrahydroquinoline derivative of claim 5 wherein R⁸ is amino, (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
- 7. (Previously presented) The tetrahydroquinoline derivative of claim 6 wherein R^8 is (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
 - 8. (Cancelled).
- 9. (Previously Presented) The tetrahydroquinoline derivative of claim 5 wherein R⁶ is (2-5C)heteroaryl or (6C)aryl.
- 10. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R⁶ is (4-5C)heteroaryl or (6C)aryl and R9 is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.
- 11. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R^7 is (di)(1-4C)alkylamino, R^8 -ethoxy, R^9 -methylamino or R^9 -methoxy and R^9 is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

Application No. 10/540,336 Docket No.: 2002.750US

Amendment dated May 5, 2009 Reply to Office Action of November 5, 2008

12. (Previously presented) The tetrahydroguinoline derivative of claim 1 wherein R⁸ is (di)(1-4C)alkylamino or (4-5C)heterocycloalkyl and R⁹ is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

- (Previously presented) A pharmaceutical composition comprising the 13. tetrahydroquinoline derivative of claim 1 and at least one pharmaceutically suitable auxiliary.
 - 14. (Cancelled)
 - 15. (Cancelled)
- 16. (Currently Amended) A method of fertility regulation comprising administering an FSH receptor activity modulating amount of the pharmaceutical composition of claim 13 to a patient in need thereof, wherein the fertility regulation is contraception in a female.